ReviewInternational journal of nanomedicine2026
SmartLipids in Drug Delivery: Redefining the Third Generation of Lipid Nanocarriers for Clinical and Industrial Translation.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SmartLipids represent the third generation of lipid-based nanocarriers, emerging as a transformative innovation in modern drug delivery and formulation science. Evolving from solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), SmartLipids overcome key limitations such as low drug loading, polymorphic instability, and limited scalability. Characterized by a "chaotic" matrix of 5-10 structurally diverse lipids, SmartLipids enable high encapsulation efficiency, enhanced physical and chemical stability, tunable drug release, and improved penetration and bioavailability for both lipophilic and amphiphilic molecules. This comprehensive review elucidates their rational design principles, formulation strategies, and key physicochemical and biological characterization parameters, supported by recent preclinical findings demonstrating superior cytocompatibility, permeability, and controlled release performance. Furthermore, we discuss the industrial translation of SmartLipids under Quality by Design (QbD) frameworks, their regulatory prospects, and their expanding applications beyond cosmetics, spanning oral, mucosal, and gene delivery systems. Collectively, SmartLipids bridge the gap between bench-scale innovation and clinical translation, offering a versatile, stable, and scalable platform for next-generation nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.